Business Wire

The Mary Kay FoundationSM and UT Southwestern Partner to End Cancers Impacting Women Globally

Share

The Mary Kay FoundationSM, a decades-long leader in the charge to eliminate cancers affecting women, recently announced a $500,000 grant to fund a groundbreaking global fellowship program with long-time partner UT Southwestern Medical Center. The new one-year fellowships will offer up to five international postdoctoral researchers the opportunity to conduct cutting-edge cancer research at the world-renowned UT Southwestern facility in Dallas, and allow them to continue research activity in their native country. This new grant program supports The Mary Kay Foundation’s continued commitment to ending women-related cancers around the world and marks the first time the Foundation’s cancer research grants program goes global.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190828005139/en/

The Mary Kay Foundation℠ has a long-standing partnership with UT Southwestern through a strong collaboration with Dr. Jerry W. Shay, cell biology professor at UT Southwestern and The Mary Kay Foundation℠ Distinguished Professorship honoree. (Photo: Mary Kay Inc.)

The Mary Kay Foundation℠ has a long-standing partnership with UT Southwestern through a strong collaboration with Dr. Jerry W. Shay, cell biology professor at UT Southwestern and The Mary Kay Foundation℠ Distinguished Professorship honoree. (Photo: Mary Kay Inc.)

“Mary Kay Ash, our founder, saw firsthand the impact that cancer had on our independent beauty consultants, their families, and women around the world,” said Ryan Rogers, board member of The Mary Kay FoundationSM and grandson of Mary Kay Ash. “It became a mission for her to eradicate cancers affecting women. Our expanded partnership with UT Southwestern will allow us to continue that lifesaving work on a global scale.”

The Mary Kay FoundationSM has a long-standing partnership with UT Southwestern through a strong collaboration with Dr. Jerry W. Shay, cell biology professor at UT Southwestern and The Mary Kay FoundationSM Distinguished Professorship honoree. Dr. Shay has served as chair of the scientific review committee for The Mary Kay Foundation Innovative/Translational Cancer Research Grant Program in the U.S. for the last 22 years and will now serve as principal investigator over the new international fellowship program.

“Expanding the program internationally will allow us to focus on cancers that affect women the most,” said Dr. Shay. “We plan to identify a group of dedicated postdoctoral candidates from around the globe, invite them to Dallas, and equip them with all the tools and resources they need to continue their groundbreaking research in our outstanding cancer lab. Their work could have a tremendous impact on how we understand and treat cancers around the world.”

Since its establishment in 1996, The Mary Kay FoundationSM has supported Mary Kay Ash’s dedication to advocating on behalf of women and her vision of creating a cancer-free world. To date, The Mary Kay FoundationSM has awarded nearly $23 million to support the work of 225 top women-related cancer researchers across the U.S., funding efforts to search for cures for breast, uterine, cervical and ovarian cancers.

“Fighting cancer was personal for Mary Kay Ash,” said Dr. Gildea, Chief Scientific Officer at Mary Kay Inc. “And it’s personal to us. She would have been proud that we’re continuing her legacy of serving women on an even larger scale.”

About The Mary Kay Foundation℠

Guided by Mary Kay Ash’s dream to enrich the lives of women everywhere, The Mary Kay FoundationSM raises and distributes funds to invest in breakthrough cancer research to find a cure for women-related cancers, and ending domestic violence against women. Since 1996, The Mary Kay FoundationSM has contributed more than $78 million to organizations aligned with its two-fold mission. In addition, the Foundation supports awareness initiatives, community outreach programs, and advocates for legislation to ensure women are healthy and safe. Together, we can make the world better for women. To learn more about how to educate, advocate, volunteer and donate, and join life-saving work to support and empower women, visit marykayfoundation.org, find us on Facebook and Instagram, or follow us on Twitter.

Contact information

The Mary Kay Foundation
marykay.com/newsroom
972.687.5332 or media@mkcorp.com

About Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Closer Collaboration between the EUIPO and EURid to Benefit SMEs25.5.2020 13:30:00 CESTPress release

The European Union Intellectual Property Office (EUIPO) and EURid, the domain name registry for the .eu, .ею and .ευ top-level domains, are set to intensify collaboration to support trade mark and domain name applicants and owners, particularly small and medium enterprises (SMEs). This collaboration will support users of the EU IP system, particularly startups, by helping them to obtain trade mark and domain name protection in a joined-up manner, so they can secure their brands from the very beginning of their business journey. At present, EU trade mark applicants are advised whether their trade mark is available as a .eu domain name at the end of the online application process at EUIPO. Applicants and holders can also set up alerts to be informed once a .eu domain name that matches their trade mark is registered. Under a new work programme agreed jointly by the two organisations, the EUIPO and EURid will explore the possibility of implementing a reciprocal process when a .eu domain na

TIP Trailer Services Announces Appointment of New CFO25.5.2020 10:05:00 CESTPress release

TIP Trailer Services, a portfolio company of I Squared Capital, has appointed Hans van Lierop as Chief Financial Officer and management board member. Hans started as CFO for TIP from Monday, 18th of May 2020 and is based in TIP’s international headquarters in Amsterdam, the Netherlands. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200525005042/en/ Hans van Lierop, appointed CFO of TIP Trailer Services (Photo: Business Wire) “I am looking forward to joining TIP’s senior leadership team and leading its Finance organisation and look forward to contributing to TIPs future success. ” Hans van Lierop commented. Hans van Lierop joins TIP with broad international experience from different industries in Europe and Africa. He has held financial leadership roles in Diageo, Airtel and Massmart Walmart. Most recently, Hans Van Lierop was CFO of Massmart Walmart, a South African retail and wholesale distributor with a turnover of US$ 7

Teva Presented New Data at the European Academy of Neurology Congress Evaluating the AJOVY ® (fremanezumab) Experience in Populations with Difficult-to-Treat Migraine25.5.2020 08:00:00 CESTPress release

Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) presented a wide range of important new data on AJOVY® (fremanezumab) and the societal and economic impact of migraine in Europe at the 6th Congress of the European Academy of Neurology (EAN). This year’s EAN congress was a virtual meeting due to the global coronavirus pandemic. The fremanezumab data included pooled analyses of the AJOVY Phase 3 clinical trials (FOCUS, HALO-episodic migraine (EM) and HALO-chronic migraine (CM)) which focused on the safety, efficacy and improved quality-of-life for patients experiencing difficult-to-treat migraine. Post-hoc analyses were also evaluated in patients who may experience challenges when managing their migraine due to comorbidities. Migraine creates a significant disease and economic burden. With more than one billion people impacted globallyi, migraine is the second leading global cause of years lived with disabilityii and annual costs of the disease in the U.S. and EU are $200 billio

JEOL: Release of a New Schottky Field Emission Scanning Electron Microscope JSM-IT80025.5.2020 08:00:00 CESTPress release

JEOL Ltd. (TOKYO:6951) (President & COO Izumi Oi) announces the release of a new Schottky field emission scanning electron microscope, JSM-IT800 in May 2020. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200524005002/en/ JSM-IT800 (Photo: Business Wire) Development Background Scanning electron microscopes (SEMs) are used in various fields, such as nanotechnology, metals, semiconductors, ceramics, medicine, and biology. As SEM applications are expanding from research and development to quality control and product inspection at manufacturing sites, SEM users are in need of faster high-quality data acquisition and simple compositional information confirmation with seamless operation. To meet these demands, the JSM-IT800, with the Intelligence Technology (IT) platform, incorporates our In-lens Schottky Plus field emission electron gun for high resolution imaging to fast elemental mapping, and an innovative electron optical cont

Ipsen: New Surveys Show Over 80% of Patients with Spasticity and Cervical Dystonia Treated with Botulinum Toxin-A Experience Debilitating Symptom Recurrence23.5.2020 07:00:00 CESTPress release

Regulatory News: Ipsen (Euronext: IPN; ADR: IPSEY) today presents the results of two patient surveys. The surveys involved over 400 respondents from five countries, living with spasticity or cervical dystonia and receiving botulinum neurotoxin type A (BoNT-A) injections. The results show that over 80% of respondents experienced debilitating symptom recurrence, and revealed that a lack of long-lasting symptom control between injections has a profound impact on the personal and professional lives of patients.1-4 “The results from these two important patient surveys provide significant insight into the real-life burden of the two conditions; however, they also highlight a worrying disconnect between patients’ treatment expectations and their actual experience. The findings, which build on our growing understanding of spasticity and cervical dystonia, provide us with the potential to unlock meaningful changes in clinical practice,” said Dr Alberto Esquenazi, Department of Physical Medicine

U.S. FDA Approves Takeda’s ALUNBRIG ® (brigatinib) as a First-Line Treatment Option for Patients Diagnosed with Rare and Serious Form of Lung Cancer22.5.2020 22:30:00 CESTPress release

Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) today announced that the U.S. Food and Drug Administration (FDA) approved ALUNBRIG (brigatinib) for adult patients with anaplastic lymphoma kinase-positive (ALK+) metastatic non-small cell lung cancer (NSCLC) as detected by an FDA-approved test. This approval expands ALUNBRIG’s current indication to include the first-line setting. ALUNBRIG is a potent and selective next-generation tyrosine kinase inhibitor (TKI) designed to target ALK molecular alterations. “We’re extremely proud of the positive results ALUNBRIG has shown for newly diagnosed ALK+ NSCLC patients, particularly those with brain metastases,” said Teresa Bitetti, President, Global Oncology Business Unit, Takeda. “Through a robust clinical development program and ongoing investigations across the NSCLC treatment landscape, Takeda is committed to uncovering solutions for people living with devastating forms of lung cancer in need of new options. We believe this approva